

Massimo Cristofanilli

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4404115/publications.pdf>

Version: 2024-02-01

235
papers

23,429
citations

19608

61
h-index

8138

148
g-index

245
all docs

245
docs citations

245
times ranked

20840
citing authors

#	ARTICLE	IF	CITATIONS
1	Synergistic PIM kinase and proteasome inhibition as a therapeutic strategy for MYC-overexpressing triple-negative breast cancer. <i>Cell Chemical Biology</i> , 2022, 29, 358-372.e5.	2.5	10
2	Standard of Care in Hormone Receptor-Positive Metastatic Breast Cancer: Can We Improve the Current Regimens or Develop Better Selection Tools?. <i>JCO Oncology Practice</i> , 2022, 18, 331-334.	1.4	4
3	Comparative transcriptional analyses of preclinical models and patient samples reveal MYC and RELA driven expression patterns that define the molecular landscape of IBC. <i>Npj Breast Cancer</i> , 2022, 8, 12.	2.3	6
4	Hotspot <i>ESR1</i> Mutations Are Multimodal and Contextual Modulators of Breast Cancer Metastasis. <i>Cancer Research</i> , 2022, 82, 1321-1339.	0.4	30
5	Exchange of cellular components between platelets and tumor cells: impact on tumor cells behavior. <i>Theranostics</i> , 2022, 12, 2150-2161.	4.6	18
6	Abstract P2-02-05: Dynamic circulating tumor cell changes in enumeration and HER2 expression during systemic therapy for metastatic breast cancer. <i>Cancer Research</i> , 2022, 82, P2-02-05-P2-02-05.	0.4	0
7	Abstract PD14-01: Comprehensive molecular characterization of patients with metastatic invasive lobular carcinoma (ILC): Using <i>real-world</i> data to describe this unique clinical entity. <i>Cancer Research</i> , 2022, 82, PD14-01-PD14-01.	0.4	0
8	Abstract P2-01-04: <i>Esr1</i> hotspot mutations in circulating tumor DNA mutation are associated with endocrine therapy resistance in metastatic breast cancer. <i>Cancer Research</i> , 2022, 82, P2-01-04-P2-01-04.	0.4	0
9	Abstract P2-07-02: Genomic predictors of rapid progression to first line endocrine and CDK4/6 inhibitor combination therapy in patients with estrogen receptor positive (ER+) HER-2 negative (HER2-) advanced breast cancer (ABC). <i>Cancer Research</i> , 2022, 82, P2-07-02-P2-07-02.	0.4	1
10	Abstract P2-01-08: <i>Esr1</i> Y537 mutations are associated with increased baseline circulating tumor cells enumeration for patients with estrogen receptor positive metastatic breast cancer. <i>Cancer Research</i> , 2022, 82, P2-01-08-P2-01-08.	0.4	0
11	Abstract P1-02-11: Somatic alterations and PD-L1 positivity in advanced breast cancer. <i>Cancer Research</i> , 2022, 82, P1-02-11-P1-02-11.	0.4	1
12	Abstract P5-17-08: A phase Ib/II study of leronlimab combined with carboplatin in patients with CCR5+ metastatic triple-negative breast cancer (mTNBC). <i>Cancer Research</i> , 2022, 82, P5-17-08-P5-17-08.	0.4	2
13	Abstract O12-11-05: SERENA-6: A Phase III study to assess the efficacy and safety of AZD9833 (camizestrant) compared with aromatase inhibitors when given in combination with palbociclib or abemaciclib in patients with HR+/HER2- metastatic breast cancer with detectable <i>ESR1</i> m who have not experienced disease progression on first-line therapy. <i>Cancer Research</i> , 2022, 82, O12-11-05-O12-11-05.	0.4	9
14	Modeling the Prognostic Impact of Circulating Tumor Cells Enumeration in Metastatic Breast Cancer for Clinical Trial Design Simulation. <i>Oncologist</i> , 2022, 27, e561-e570.	1.9	5
15	Circulating tumour cells in the -omics era: how far are we from achieving the "singularity"? <i>British Journal of Cancer</i> , 2022, 127, 173-184.	2.9	23
16	Single-Cells Isolation and Molecular Analysis: Focus on HER2-Low CTCs in Metastatic Breast Cancer. <i>Cancers</i> , 2022, 14, 79.	1.7	7
17	Overall Survival with Palbociclib and Fulvestrant in Women with HR+/HER2 ⁺ ABC: Updated Exploratory Analyses of PALOMA-3, a Double-blind, Phase III Randomized Study. <i>Clinical Cancer Research</i> , 2022, 28, 3433-3442.	3.2	65
18	Tracking changes in circulating stromal cells and circulating tumor cells predicts responsiveness of new line induction in metastatic breast cancer after 1 cycle of therapy. <i>Journal of Clinical Oncology</i> , 2022, 40, 3056-3056.	0.8	0

#	ARTICLE	IF	CITATIONS
19	Abstract LB117: Pilot study to identify live circulating tumor cells (CTCs) in metastatic breast cancer (MBC) by application of a novel microfluidic workflow system and flow cytometry. <i>Cancer Research</i> , 2022, 82, LB117-LB117.	0.4	0
20	ESR1 mutations in circulating tumor DNA (ctDNA) are associated with CTCs and increased hormone receptors in metastatic tumor tissues of patients with metastatic breast cancer (MBC).. <i>Journal of Clinical Oncology</i> , 2022, 40, 1057-1057.	0.8	0
21	Genomic Aberrations in Circulating Tumor DNAs from Palbociclib-Treated Metastatic Breast Cancer Patients Reveal a Novel Resistance Mechanism. <i>Cancers</i> , 2022, 14, 2872.	1.7	1
22	CK+/CD45+ (dual-positive) circulating cells are associated with prognosis in patients with advanced breast cancer.. <i>Journal of Clinical Oncology</i> , 2022, 40, 1093-1093.	0.8	2
23	Genomic Landscape of Advanced Solid Tumors in Circulating Tumor DNA and Correlation With Tissue Sequencing: A Single Institution's Experience. <i>JCO Precision Oncology</i> , 2022, , .	1.5	9
24	Defining resistance mechanisms to CDK4/6 inhibition in hormone receptor-positive HER2-negative metastatic breast cancer (MBC) through a machine learning approach applied to circulating tumor DNA (ctDNA).. <i>Journal of Clinical Oncology</i> , 2022, 40, 3055-3055.	0.8	0
25	Circulating Tumor DNA Markers for Early Progression on Fulvestrant With or Without Palbociclib in ER+ Advanced Breast Cancer. <i>Journal of the National Cancer Institute</i> , 2021, 113, 309-317.	3.0	60
26	Understanding the organ tropism of metastatic breast cancer through the combination of liquid biopsy tools. <i>European Journal of Cancer</i> , 2021, 143, 147-157.	1.3	32
27	Expected Medium- and Long-Term Impact of the COVID-19 Outbreak in Oncology. <i>JCO Global Oncology</i> , 2021, 7, 162-172.	0.8	38
28	Surfactant-assisted one-pot sample preparation for label-free single-cell proteomics. <i>Communications Biology</i> , 2021, 4, 265.	2.0	46
29	Long-Term Pooled Safety Analysis of Palbociclib in Combination with Endocrine Therapy for Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: Updated Analysis with up to 5â€“Years of Follow-Up. <i>Oncologist</i> , 2021, 26, e749-e755.	1.9	33
30	Comparative effectiveness of first-line palbociclib plus letrozole versus letrozole alone for HR+/HER2âˆ“ metastatic breast cancer in US real-world clinical practice. <i>Breast Cancer Research</i> , 2021, 23, 37.	2.2	65
31	New Treatment Strategies for the Inflammatory Breast Cancer. <i>Current Treatment Options in Oncology</i> , 2021, 22, 50.	1.3	10
32	Landscape of GATA3 mutations identified from circulating tumor DNA clinical testing and their impact on disease outcomes in estrogen receptor-positive (ER+) metastatic breast cancers treated with endocrine therapies.. <i>Journal of Clinical Oncology</i> , 2021, 39, 1065-1065.	0.8	1
33	Overall survival (OS) with palbociclib (PAL) + fulvestrant (FUL) in women with hormone receptorâˆ“positive (HR+), human epidermal growth factor receptor 2âˆ“negative (HER2âˆ“) advanced breast cancer (ABC): Updated analyses from PALOMA-3.. <i>Journal of Clinical Oncology</i> , 2021, 39, 1000-1000.	0.8	47
34	Longitudinal Dynamics of Circulating Tumor Cells and Circulating Tumor DNA for Treatment Monitoring in Metastatic Breast Cancer. <i>JCO Precision Oncology</i> , 2021, 5, 943-952.	1.5	23
35	Open-label, multicenter, phase 1b/2 study of rebastinib in combination with paclitaxel to assess safety and efficacy in patients with advanced or metastatic endometrial cancer.. <i>Journal of Clinical Oncology</i> , 2021, 39, 5576-5576.	0.8	1
36	Precision Oncology. <i>Advances in Oncology</i> , 2021, 1, 97-112.	0.1	0

#	ARTICLE	IF	CITATIONS
37	Circulating Tumor Cell Clusters Are Frequently Detected in Women with Early-Stage Breast Cancer. <i>Cancers</i> , 2021, 13, 2356.	1.7	26
38	Prognostic Factors for Overall Survival in Patients with Hormone Receptor-Positive Advanced Breast Cancer: Analyses From PALOMA-3. <i>Oncologist</i> , 2021, 26, e1339-e1346.	1.9	16
39	Evaluation of the Association of Polymorphisms With Palbociclib-Induced Neutropenia: Pharmacogenetic Analysis of PALOMA-2/-3. <i>Oncologist</i> , 2021, 26, e1143-e1155.	1.9	15
40	Whole-exome sequencing identifies somatic mutations and intratumor heterogeneity in inflammatory breast cancer. <i>Npj Breast Cancer</i> , 2021, 7, 72.	2.3	15
41	Circulating tumor cells, circulating tumor DNA, and disease characteristics in young women with metastatic breast cancer. <i>Breast Cancer Research and Treatment</i> , 2021, 187, 397-405.	1.1	8
42	Targeting a cell surface vitamin D receptor on tumor-associated macrophages in triple-negative breast cancer. <i>ELife</i> , 2021, 10, .	2.8	18
43	Genetic Variants and Tumor Immune Microenvironment: Clues for Targeted Therapies in Inflammatory Breast Cancer (IBC). <i>International Journal of Molecular Sciences</i> , 2021, 22, 8924.	1.8	1
44	ICAM1 initiates CTC cluster formation and trans-endothelial migration in lung metastasis of breast cancer. <i>Nature Communications</i> , 2021, 12, 4867.	5.8	97
45	Cell-free DNA comparative analysis of the genomic landscape of first-line hormone receptor-positive metastatic breast cancer from the US and China. <i>Breast Cancer Research and Treatment</i> , 2021, 190, 213-226.	1.1	2
46	Liquid biopsy from research to clinical practice: focus on non-small cell lung cancer. <i>Expert Review of Molecular Diagnostics</i> , 2021, 21, 1165-1178.	1.5	20
47	Understanding metastasis in breast cancer to improve detection, monitoring and treatment. <i>Critical Reviews in Oncology/Hematology</i> , 2021, 167, 103462.	2.0	0
48	EGFR inhibition blocks cancer stem cell clustering and lung metastasis of triple negative breast cancer. <i>Theranostics</i> , 2021, 11, 6632-6643.	4.6	38
49	The Use of Serial Circulating Tumor DNA to Detect Resistance Alterations in Progressive Metastatic Breast Cancer. <i>Clinical Cancer Research</i> , 2021, 27, 1361-1370.	3.2	25
50	The curious phenomenon of dual-positive circulating cells: Longtime overlooked tumor cells. <i>Seminars in Cancer Biology</i> , 2020, 60, 344-350.	4.3	26
51	Efficacy and safety of palbociclib plus endocrine therapy in North American women with hormone receptor-positive/human epidermal growth factor receptor 2-negative metastatic breast cancer. <i>Breast Journal</i> , 2020, 26, 368-375.	0.4	8
52	Performance of a novel Next Generation Sequencing circulating tumor DNA (ctDNA) platform for the evaluation of samples from patients with metastatic breast cancer (MBC). <i>Critical Reviews in Oncology/Hematology</i> , 2020, 145, 102856.	2.0	17
53	NOTCH and DNA repair pathways are more frequently targeted by genomic alterations in inflammatory than in non-inflammatory breast cancers. <i>Molecular Oncology</i> , 2020, 14, 504-519.	2.1	23
54	Time for a shift in molecular down staging in luminal breast cancer. <i>Lancet Oncology</i> , The, 2020, 21, 2-3.	5.1	3

#	ARTICLE	IF	CITATIONS
55	Precision Prevention and Cancer Interception: The New Challenges of Liquid Biopsy. <i>Cancer Discovery</i> , 2020, 10, 1635-1644.	7.7	52
56	International liquid biopsy standardization alliance white paper. <i>Critical Reviews in Oncology/Hematology</i> , 2020, 156, 103112.	2.0	66
57	Treatment effect of palbociclib plus endocrine therapy by prognostic and intrinsic subtype and biomarker analysis in patients with bone-only disease: a joint analysis of PALOMA-2 and PALOMA-3 clinical trials. <i>Breast Cancer Research and Treatment</i> , 2020, 184, 23-35.	1.1	21
58	Landscape of circulating tumour DNA in metastatic breast cancer. <i>EBioMedicine</i> , 2020, 58, 102914.	2.7	40
59	Oncological care organisation during COVID-19 outbreak. <i>ESMO Open</i> , 2020, 5, e000853.	2.0	29
60	Prognostic value of HER2 status on circulating tumor cells in advanced-stage breast cancer patients with HER2-negative tumors. <i>Breast Cancer Research and Treatment</i> , 2020, 181, 679-689.	1.1	30
61	Overall Survival of CDK4/6-Inhibitor-Based Treatments in Clinically Relevant Subgroups of Metastatic Breast Cancer: Systematic Review and Meta-Analysis. <i>Journal of the National Cancer Institute</i> , 2020, 112, 1089-1097.	3.0	59
62	Hormone Receptor-Positive/Human Epidermal Growth Receptor 2-Negative Metastatic Breast Cancer in Young Women: Emerging Data in the Era of Molecularly Targeted Agents. <i>Oncologist</i> , 2020, 25, e900-e908.	1.9	15
63	Hematologic adverse events following palbociclib dose reduction in patients with hormone receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer: pooled analysis from randomized phase 2 and 3 studies. <i>Breast Cancer Research</i> , 2020, 22, 27.	2.2	24
64	Minimal Residual Disease in Patients With Nonmetastatic Triple-Negative Breast Cancer. <i>JAMA Oncology</i> , 2020, 6, 1332.	3.4	2
65	Regulation of KLF4 by posttranslational modification circuitry in endocrine resistance. <i>Cellular Signalling</i> , 2020, 70, 109574.	1.7	7
66	Routine Plasma-Based Genotyping to Comprehensively Detect Germline, Somatic, and Reversion <i>BRCA</i> Mutations among Patients with Advanced Solid Tumors. <i>Clinical Cancer Research</i> , 2020, 26, 2546-2555.	3.2	33
67	The Landscape of Targeted Therapies in TNBC. <i>Cancers</i> , 2020, 12, 916.	1.7	232
68	Challenges and opportunities of cfDNA analysis implementation in clinical practice: Perspective of the International Society of Liquid Biopsy (ISLB). <i>Critical Reviews in Oncology/Hematology</i> , 2020, 151, 102978.	2.0	79
69	Abstract P1-19-02: Overall survival for first-line palbociclib plus letrozole vs letrozole alone for HR+/HER2- metastatic breast cancer patients in US real-world clinical practice. , 2020, , .		13
70	Keeping oncologists current with CDK4/6 inhibitors in HR+ breast cancer: The impact of online education.. <i>Journal of Clinical Oncology</i> , 2020, 38, e13044-e13044.	0.8	0
71	ERBB2 amplifications and mutations in 109 advanced breast cancer patients by next-generation sequencing.. <i>Journal of Clinical Oncology</i> , 2020, 38, 3565-3565.	0.8	1
72	The landscape of genomic alterations detected in serial circulating tumor DNA (ctDNA) in clinical progressive metastatic breast cancer.. <i>Journal of Clinical Oncology</i> , 2020, 38, 1084-1084.	0.8	0

#	ARTICLE	IF	CITATIONS
73	Circulating tumor DNA (ctDNA) to evaluate stage III and stage IV metastatic breast cancer (MBC), describe tumor heterogeneity, and outcome.. Journal of Clinical Oncology, 2020, 38, 1028-1028.	0.8	0
74	Cell-free DNA comparative analysis of hormone receptor-positive, first-line metastatic breast cancer genomic landscape in the United States and China.. Journal of Clinical Oncology, 2020, 38, 1059-1059.	0.8	11
75	Chemokine signaling and MAPK/ERK pathway for advanced prostate cancer treatment response.. Journal of Clinical Oncology, 2020, 38, TPS275-TPS275.	0.8	1
76	New insight into the significance of KLF4 PARylation in genome stability, carcinogenesis, and therapy. EMBO Molecular Medicine, 2020, 12, e12391.	3.3	14
77	IMPAssionate about immunotherapy for TNBC: from change, to revolution and to cure?. Annals of Translational Medicine, 2020, 8, 1537.	0.7	0
78	Long-term Pooled Safety Analysis of Palbociclib in Combination With Endocrine Therapy for HR+/HER2-Advanced Breast Cancer. Journal of the National Cancer Institute, 2019, 111, 419-430.	3.0	55
79	Association between circulating tumor cells and peripheral blood monocytes in metastatic breast cancer. Therapeutic Advances in Medical Oncology, 2019, 11, 175883591986606.	1.4	35
80	Perspectives on Inflammatory Breast Cancer (IBC) Research, Clinical Management and Community Engagement from the Duke IBC Consortium. Journal of Cancer, 2019, 10, 3344-3351.	1.2	19
81	Emerging Role of Genomics and Cell-Free DNA in Breast Cancer. Current Treatment Options in Oncology, 2019, 20, 68.	1.3	9
82	A novel strategy to block mitotic progression for targeted therapy. EBioMedicine, 2019, 49, 40-54.	2.7	33
83	Endocrine treatment versus chemotherapy in postmenopausal women with hormone receptor-positive, HER2-negative, metastatic breast cancer: a systematic review and network meta-analysis. Lancet Oncology, The, 2019, 20, 1360-1369.	5.1	131
84	Comparison of BEAMing and Droplet Digital PCR for Circulating Tumor DNA Analysis. Clinical Chemistry, 2019, 65, 1405-1413.	1.5	53
85	Circulating tumor cell and cell-free RNA capture and expression analysis identify platelet-associated genes in metastatic lung cancer. BMC Cancer, 2019, 19, 603.	1.1	29
86	Recent advances with cyclin-dependent kinase inhibitors: therapeutic agents for breast cancer and their role in immuno-oncology. Expert Review of Anticancer Therapy, 2019, 19, 569-587.	1.1	21
87	A novel small-molecule antagonizes PRMT5-mediated KLF4 methylation for targeted therapy. EBioMedicine, 2019, 44, 98-111.	2.7	27
88	Patient-centered engagement and symptom/toxicity monitoring in the new era of tumor next-generation sequencing and immunotherapy: The OncoTool and OncoPRO platforms. Cancer, 2019, 125, 2338-2344.	2.0	7
89	Tucidinostat plus exemestane for postmenopausal patients with advanced, hormone receptor-positive breast cancer (ACE): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncology, The, 2019, 20, 806-815.	5.1	154
90	Aberrant FGFR signaling mediates resistance to CDK4/6 inhibitors in ER+ breast cancer. Nature Communications, 2019, 10, 1373.	5.8	252

#	ARTICLE	IF	CITATIONS
91	Circulating Tumor Cells With Epithelial-to-mesenchymal Transition Phenotypes Associated With Inferior Outcomes in Primary Breast Cancer. <i>Anticancer Research</i> , 2019, 39, 1829-1837.	0.5	49
92	Cyclin E1 Expression and Palbociclib Efficacy in Previously Treated Hormone Receptor-Positive Metastatic Breast Cancer. <i>Journal of Clinical Oncology</i> , 2019, 37, 1169-1178.	0.8	266
93	Current state of clinical trials in breast cancer brain metastases. <i>Neuro-Oncology Practice</i> , 2019, 6, 392-401.	1.0	16
94	Association of a novel circulating tumor DNA next-generation sequencing platform with circulating tumor cells (CTCs) and CTC clusters in metastatic breast cancer. <i>Breast Cancer Research</i> , 2019, 21, 137.	2.2	42
95	Association of clinical outcomes in metastatic breast cancer patients with circulating tumour cell and circulating cell-free DNA. <i>European Journal of Cancer</i> , 2019, 106, 133-143.	1.3	35
96	The clinical use of circulating tumor cells (CTCs) enumeration for staging of metastatic breast cancer (MBC): International expert consensus paper. <i>Critical Reviews in Oncology/Hematology</i> , 2019, 134, 39-45.	2.0	200
97	Circulating tumor DNA analysis in breast cancer: Is it ready for prime-time?. <i>Cancer Treatment Reviews</i> , 2019, 73, 73-83.	3.4	88
98	Homophilic CD44 Interactions Mediate Tumor Cell Aggregation and Polyclonal Metastasis in Patient-Derived Breast Cancer Models. <i>Cancer Discovery</i> , 2019, 9, 96-113.	7.7	256
99	Comparing the Performances of Magnetic Resonance Imaging Size vs Pharmacokinetic Parameters to Predict Response to Neoadjuvant Chemotherapy and Survival in Patients With Breast Cancer. <i>Current Problems in Diagnostic Radiology</i> , 2019, 48, 235-240.	0.6	15
100	Genomic markers of early progression on fulvestrant with or without palbociclib for ER+ advanced breast cancer in the PALOMA-3 trial.. <i>Journal of Clinical Oncology</i> , 2019, 37, 1010-1010.	0.8	8
101	Association of drug-related polymorphisms with palbociclib-related neutropenia: Pharmacogenetic analysis of PALOMA-2/3 (P2/3).. <i>Journal of Clinical Oncology</i> , 2019, 37, 1060-1060.	0.8	2
102	A phase II study of pembrolizumab and capecitabine for triple-negative (TN) and hormone receptor-positive, HER2-negative endocrine-refractory metastatic breast cancer (MBC).. <i>Journal of Clinical Oncology</i> , 2019, 37, 1096-1096.	0.8	4
103	Accelerating advanced precision medicine through a harmonized data exchange platform and research consortium (PMEC).. <i>Journal of Clinical Oncology</i> , 2019, 37, 6557-6557.	0.8	0
104	Can the enumeration of circulating tumor cells (CTCs) and the characterization of circulating tumor DNA (ctDNA) provide insight into organ tropism in metastatic breast cancer (MBC)?. <i>Journal of Clinical Oncology</i> , 2019, 37, 3038-3038.	0.8	1
105	Association of HER2 alterations and ESR1 mutations in cell-free DNA (cfDNA) with circulating tumor cells (CTCs), multiple metastasis, and prognosis in stage III/IV breast cancer (BCa).. <i>Journal of Clinical Oncology</i> , 2019, 37, 1036-1036.	0.8	0
106	Real-time monitoring of circulating stromal cells in the blood to predict responsiveness of new-line therapies in metastatic breast cancer.. <i>Journal of Clinical Oncology</i> , 2019, 37, e14048-e14048.	0.8	0
107	Early circulating tumor DNA dynamics and clonal selection with palbociclib and fulvestrant for breast cancer. <i>Nature Communications</i> , 2018, 9, 896.	5.8	305
108	Perspective on Circulating Tumor Cell Clusters: Why It Takes a Village to Metastasize. <i>Cancer Research</i> , 2018, 78, 845-852.	0.4	169

#	ARTICLE	IF	CITATIONS
109	Efficacy Against Human Prostate Cancer by Prostate-specific Membrane Antigen-specific, Transforming Growth Factor- β 2 Inensitive Genetically Targeted CD8+ T-cells Derived from Patients with Metastatic Castrate-resistant Disease. <i>European Urology</i> , 2018, 73, 648-652.	0.9	43
110	Association of Circulating Tumor Cell Status With Benefit of Radiotherapy and Survival in Early-Stage Breast Cancer. <i>JAMA Oncology</i> , 2018, 4, e180163.	3.4	105
111	Decreased expression of microRNA-26b in locally advanced and inflammatory breast cancer. <i>Human Pathology</i> , 2018, 77, 121-129.	1.1	20
112	Anaplastic Lymphoma Kinase Mutation (<i>ALK</i> F1174C) in Small Cell Carcinoma of the Prostate and Molecular Response to Alectinib. <i>Clinical Cancer Research</i> , 2018, 24, 2732-2739.	3.2	30
113	Cell-Free DNA and Circulating Tumor Cells: Comprehensive Liquid Biopsy Analysis in Advanced Breast Cancer. <i>Clinical Cancer Research</i> , 2018, 24, 560-568.	3.2	120
114	Emerging Innovative Therapeutic Approaches Leveraging Cyclin-Dependent Kinase Inhibitors to Treat Advanced Breast Cancer. <i>Clinical Pharmacology and Therapeutics</i> , 2018, 103, 1009-1019.	2.3	5
115	Predictors of prolonged benefit from palbociclib plus fulvestrant in women with endocrine-resistant hormone receptor-positive/human epidermal growth factor receptor 2-negative metastatic breast cancer in PALOMA-3. <i>European Journal of Cancer</i> , 2018, 104, 21-31.	1.3	53
116	Overall Survival with Palbociclib and Fulvestrant in Advanced Breast Cancer. <i>New England Journal of Medicine</i> , 2018, 379, 1926-1936.	13.9	805
117	The Genetic Landscape and Clonal Evolution of Breast Cancer Resistance to Palbociclib plus Fulvestrant in the PALOMA-3 Trial. <i>Cancer Discovery</i> , 2018, 8, 1390-1403.	7.7	397
118	Phase I study of alpelisib (BYL-719) and trastuzumab emtansine (T-DM1) in HER2-positive metastatic breast cancer (MBC) after trastuzumab and taxane therapy. <i>Breast Cancer Research and Treatment</i> , 2018, 171, 371-381.	1.1	100
119	Caloric restriction counteracts chemotherapy-induced inflammation and increases response to therapy in a triple negative breast cancer model. <i>Cell Cycle</i> , 2018, 17, 1536-1544.	1.3	35
120	International Consensus on the Clinical Management of Inflammatory Breast Cancer from the Morgan Welch Inflammatory Breast Cancer Research Program 10th Anniversary Conference. <i>Journal of Cancer</i> , 2018, 9, 1437-1447.	1.2	84
121	From the Past to the Present: Insurer Coverage Frameworks for Next-Generation Tumor Sequencing. <i>Value in Health</i> , 2018, 21, 1062-1068.	0.1	19
122	Regarding the Congruence Between 2 Circulating Tumor DNA Sequencing Assays. <i>JAMA Oncology</i> , 2018, 4, 1430.	3.4	2
123	NQO1 regulates mitotic progression and response to mitotic stress through modulating SIRT2 activity. <i>Free Radical Biology and Medicine</i> , 2018, 126, 358-371.	1.3	12
124	Impeding Circulating Tumor Cell Reseeding Decelerates Metastatic Progression and Potentiates Chemotherapy. <i>Molecular Cancer Research</i> , 2018, 16, 1844-1854.	1.5	6
125	Genetic landscape of resistance to CDK4/6 inhibition in circulating tumor DNA (ctDNA) analysis of the PALOMA3 trial of palbociclib and fulvestrant versus placebo and fulvestrant.. <i>Journal of Clinical Oncology</i> , 2018, 36, 1001-1001.	0.8	11
126	The impact of circulating tumor cells (CTCs) detection in metastatic breast cancer (MBC): Implications of indolent-stage IV disease (Stage IV _{indolent}).. <i>Journal of Clinical Oncology</i> , 2018, 36, 1019-1019.	0.8	3

#	ARTICLE	IF	CITATIONS
127	Treatment effect of palbociclib (PAL) plus endocrine therapy (ET) by prognostic and intrinsic subtype: A joint analysis of PALOMA2 and PALOMA3.. Journal of Clinical Oncology, 2018, 36, 1023-1023.	0.8	1
128	Dynamic changes of interleukin 2 (IL-2) and circulating tumor cells (CTCs) in patients with advanced breast cancer (BCa) after systemic therapies.. Journal of Clinical Oncology, 2018, 36, 1090-1090.	0.8	2
129	Landscape of BRCA1 and BRCA2 germline, somatic, and reversion alterations detectable by cell-free DNA testing among patients with metastatic breast, ovarian, pancreatic, or prostate cancer.. Journal of Clinical Oncology, 2018, 36, 12097-12097.	0.8	1
130	Palbociclib after CDK and endocrine therapy (PACE): A randomized phase II study of fulvestrant, palbociclib, and avelumab for endocrine pre-treated ER+/HER2- metastatic breast cancer.. Journal of Clinical Oncology, 2018, 36, TPS1104-TPS1104.	0.8	13
131	Genomic alterations at the basis of treatment resistance in metastatic breast cancer: clinical applications. Oncotarget, 2018, 9, 31606-31619.	0.8	11
132	Antineoplastic effects of selective CDK9 inhibition with atuveciclib on cancer stem-like cells in triple-negative breast cancer. Oncotarget, 2018, 9, 37305-37318.	0.8	19
133	Combining circulating tumor cells and circulating cancer associated macrophage-like cells for accurately predicting responsiveness of new line therapies in late stage cancers.. Journal of Clinical Oncology, 2018, 36, 12032-12032.	0.8	0
134	Circulating tumor cells enumeration (CTCs) and circulating tumor DNA (ctDNA): Clinical and molecular features of "rapidly progressing" stage IV disease (Stage IVprog).. Journal of Clinical Oncology, 2018, 36, 12040-12040.	0.8	0
135	Integration of lymphocyte ratios (LRs) and circulating tumor cells (CTCs) characterization: The interplay between immunity and metastatic breast cancer (MBC).. Journal of Clinical Oncology, 2018, 36, 12039-12039.	0.8	0
136	Hematologic adverse events following palbociclib (PAL) dose reduction in patients (pts) with hormone receptor-positive (HR+)/human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (ABC): Pooled analysis from randomized phase 2 and 3 studies.. Journal of Clinical Oncology, 2018, 36, 1060-1060.	0.8	2
137	Targeting Epidermal Growth Factor Receptor in triple negative breast cancer: New discoveries and practical insights for drug development. Cancer Treatment Reviews, 2017, 53, 111-119.	3.4	134
138	Mutational studies on single circulating tumor cells isolated from the blood of inflammatory breast cancer patients. Breast Cancer Research and Treatment, 2017, 163, 219-230.	1.1	40
139	The Growing Role of CDK4/6 Inhibitors in Treating Hormone Receptor-Positive Advanced Breast Cancer. Current Treatment Options in Oncology, 2017, 18, 6.	1.3	44
140	Concordance of Genomic Alterations by Next-Generation Sequencing in Tumor Tissue versus Circulating Tumor DNA in Breast Cancer. Molecular Cancer Therapeutics, 2017, 16, 1412-1420.	1.9	114
141	Response rate as a potential surrogate for survival and efficacy in patients treated with novel immune checkpoint inhibitors: A meta-regression of randomised prospective studies. European Journal of Cancer, 2017, 86, 257-265.	1.3	31
142	Detection of Activating Estrogen Receptor Gene (<i>ESR1</i>) Mutations in Single Circulating Tumor Cells. Clinical Cancer Research, 2017, 23, 6086-6093.	3.2	68
143	Prognostic values of cancer associated macrophage-like cells (CAML) enumeration in metastatic breast cancer. Breast Cancer Research and Treatment, 2017, 165, 733-741.	1.1	27
144	Palbociclib Combined with Fulvestrant in Premenopausal Women with Advanced Breast Cancer and Prior Progression on Endocrine Therapy: PALOMA-3 Results. Oncologist, 2017, 22, 1028-1038.	1.9	108

#	ARTICLE	IF	CITATIONS
145	Longitudinally collected CTCs and CTC-clusters and clinical outcomes of metastatic breast cancer. Breast Cancer Research and Treatment, 2017, 161, 83-94.	1.1	156
146	Scientific Summary from the Morgan Welch MD Anderson Cancer Center Inflammatory Breast Cancer (IBC) Program 10th Anniversary Conference. Journal of Cancer, 2017, 8, 3607-3614.	1.2	15
147	Toxicity profile of approved anti-PD-1 monoclonal antibodies in solid tumors: a systematic review and meta-analysis of randomized clinical trials. Oncotarget, 2017, 8, 8910-8920.	0.8	108
148	Developmental therapeutics for inflammatory breast cancer: Biology and translational directions. Oncotarget, 2017, 8, 12417-12432.	0.8	24
149	Phase I study of alpelisib (BYL-719) and T-DM1 in HER2-positive metastatic breast cancer after trastuzumab and taxane therapy.. Journal of Clinical Oncology, 2017, 35, 1026-1026.	0.8	14
150	Predictors of prolonged benefit from palbociclib (PAL) plus fulvestrant (F) in women with endocrine-resistant hormone receptorâ€“positive/human epidermal growth factor receptor 2â€“negative (HR+/HER2â€“) advanced breast cancer (ABC) in PALOMA-3.. Journal of Clinical Oncology, 2017, 35, 1050-1050.	0.8	2
151	Palbociclib exposure-response analyses in second-line treatment of hormone-receptor positive advanced breast cancer (ABC).. Journal of Clinical Oncology, 2017, 35, 1053-1053.	0.8	7
152	Cancer-associated macrophage-like cells as prognostic indicators of overall survival in a variety of solid malignancies.. Journal of Clinical Oncology, 2017, 35, 11503-11503.	0.8	9
153	Identification of putative germline mutations in 10,288 patients undergoing circulating tumor DNA testing.. Journal of Clinical Oncology, 2017, 35, 1514-1514.	0.8	3
154	Durvalumab and tremelimumab in metastatic breast cancer (MBC): Immunotherapy and immunopharmacogenomic dynamics.. Journal of Clinical Oncology, 2017, 35, 3052-3052.	0.8	18
155	Concordance of mutations identified using circulating tumor DNA (ctDNA) compared to tissue based next generation sequencing (NGS) in gastrointestinal malignancies: A single institution experience.. Journal of Clinical Oncology, 2017, 35, e23023-e23023.	0.8	2
156	Comparison of tumor mutational burden (TMB) across tumor tissue and circulating tumor DNA (ctDNA).. Journal of Clinical Oncology, 2017, 35, e23028-e23028.	0.8	20
157	A pilot study of palbociclib in patients with HER2-positive breast cancer with brain metastasis.. Journal of Clinical Oncology, 2017, 35, TPS1110-TPS1110.	0.8	5
158	Circulating tumor cells (CTCs) are associated with abnormalities in peripheral blood dendritic cells in patients with inflammatory breast cancer. Oncotarget, 2017, 8, 35656-35668.	0.8	44
159	Experience of implementing a novel random sampling BICR audit for investigator (INV)-assessed progression-free survival (PFS) in the PALOMA-3 trial.. Journal of Clinical Oncology, 2017, 35, 1058-1058.	0.8	0
160	Predicting sensitivity to palbociclib with early circulating tumor DNA dynamics in the PALOMA-3 trial.. Journal of Clinical Oncology, 2017, 35, 1018-1018.	0.8	6
161	Concordance between genomic alterations assessed by next-generation sequencing in tumor tissue or circulating cell-free DNA. Oncotarget, 2016, 7, 65364-65373.	0.8	99
162	Detection and Characterization of Circulating Tumor Associated Cells in Metastatic Breast Cancer. International Journal of Molecular Sciences, 2016, 17, 1665.	1.8	63

#	ARTICLE	IF	CITATIONS
163	Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial. <i>Lancet Oncology, The</i> , 2016, 17, 425-439.	5.1	1,344
164	The effects of CEP-37440, an inhibitor of focal adhesion kinase, in vitro and in vivo on inflammatory breast cancer cells. <i>Breast Cancer Research</i> , 2016, 18, 37.	2.2	21
165	Circulating Cancer-Associated Macrophage-Like Cells Differentiate Malignant Breast Cancer and Benign Breast Conditions. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2016, 25, 1037-1042.	1.1	61
166	Genomic and Immunological Tumor Profiling Identifies Targetable Pathways and Extensive CD8+/PDL1+ Immune Infiltration in Inflammatory Breast Cancer Tumors. <i>Molecular Cancer Therapeutics</i> , 2016, 15, 1746-1756.	1.9	45
167	Clinical-pathological features and treatment modalities associated with recurrence in DCIS and micro-invasive carcinoma: Who to treat more and who to treat less. <i>Breast</i> , 2016, 29, 223-230.	0.9	11
168	Metastatic breast cancer: focus on endocrine sensitivity. <i>Lancet, The</i> , 2016, 388, 2961-2962.	6.3	2
169	Palbociclib in Combination With Fulvestrant in Women With Hormone Receptor-Positive/HER2-Negative Advanced Metastatic Breast Cancer: Detailed Safety Analysis From a Multicenter, Randomized, Placebo-Controlled, Phase III Study (PALOMA-3). <i>Oncologist</i> , 2016, 21, 1165-1175.	1.9	183
170	GSK-3 inhibition overcomes chemoresistance in human breast cancer. <i>Cancer Letters</i> , 2016, 380, 384-392.	3.2	55
171	Towards a transcriptome-based theranostic platform for unfavorable breast cancer phenotypes. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2016, 113, 12780-12785.	3.3	31
172	Real-time HER2 status detected on circulating tumor cells predicts different outcomes of anti-HER2 therapy in histologically HER2-positive metastatic breast cancer patients. <i>BMC Cancer</i> , 2016, 16, 526.	1.1	28
173	Plasma <i>ESR1</i> Mutations and the Treatment of Estrogen Receptor-Positive Advanced Breast Cancer. <i>Journal of Clinical Oncology</i> , 2016, 34, 2961-2968.	0.8	573
174	Prospective changes in global DNA methylation and cancer incidence and mortality. <i>British Journal of Cancer</i> , 2016, 115, 465-472.	2.9	41
175	Inflammatory breast cancer: a new approach. <i>Lancet Oncology, The</i> , 2016, 17, 544-546.	5.1	20
176	MicroRNA expression profiling identifies decreased expression of miR-205 in inflammatory breast cancer. <i>Modern Pathology</i> , 2016, 29, 330-346.	2.9	33
177	Correlation of circulating tumor cells (CTCs) with peripheral blood leukocytes to predict outcome in metastatic breast cancer (MBC).. <i>Journal of Clinical Oncology</i> , 2016, 34, 11532-11532.	0.8	2
178	Toxicity profile of approved anti-PD1 monoclonal antibodies in solid tumors: A systematic review and meta-analysis of randomized clinical trials.. <i>Journal of Clinical Oncology</i> , 2016, 34, 3064-3064.	0.8	1
179	Efficacy of palbociclib plus fulvestrant (P+F) in patients (pts) with metastatic breast cancer (MBC) and <i>ESR1</i> mutations (mus) in circulating tumor DNA (ctDNA).. <i>Journal of Clinical Oncology</i> , 2016, 34, 512-512.	0.8	17
180	Palbociclib (PAL) in combination with fulvestrant (F) in pre-/peri-menopausal (PreM) women with metastatic breast cancer (MBC) and prior progression on endocrine therapy – results from Paloma-3.. <i>Journal of Clinical Oncology</i> , 2016, 34, 524-524.	0.8	8

#	ARTICLE	IF	CITATIONS
181	Development of an Automated and Sensitive Microfluidic Device for Capturing and Characterizing Circulating Tumor Cells (CTCs) from Clinical Blood Samples. PLoS ONE, 2016, 11, e0147400.	1.1	82
182	Circulating cancer associated macrophage-like cells in the detection of invasive breast cancer.. Journal of Clinical Oncology, 2016, 34, e23055-e23055.	0.8	0
183	Concordance of genomic alterations by next generation sequencing (NGS) in tumor tissue vs. cell-free DNA in advanced breast cancer.. Journal of Clinical Oncology, 2016, 34, 11528-11528.	0.8	0
184	Circulating tumor cells (CTCs) and circulating tumor DNA (ctDNA) longitudinal monitoring of metastatic breast cancer (MBC).. Journal of Clinical Oncology, 2016, 34, e23030-e23030.	0.8	0
185	Genomic aberrations in advanced solid malignancies using next generation sequencing: A single institution experience.. Journal of Clinical Oncology, 2016, 34, e23206-e23206.	0.8	0
186	A Preclinical Model of Inflammatory Breast Cancer to Study the Involvement of CXCR4 and ACKR3 in the Metastatic Process. Translational Oncology, 2015, 8, 358-367.	1.7	13
187	Palbociclib in Hormone-Receptorâ€“Positive Advanced Breast Cancer. New England Journal of Medicine, 2015, 373, 209-219.	13.9	1,239
188	Using circulating tumor cells to guide therapy in breast cancer: could this replace biopsies?. Pharmacogenomics, 2015, 16, 669-672.	0.6	1
189	Neoadjuvant Model in Cancer Treatment: From Clinical Opportunity to Health-Care Utility. Journal of the National Cancer Institute Monographs, 2015, 2015, 1-3.	0.9	0
190	Inflammatory Breast Cancer Management in the National Comprehensive Cancer Network: The Disease, Recurrence Pattern, and Outcome. Clinical Breast Cancer, 2015, 15, 1-7.	1.1	85
191	Circulating tumor cells in newly diagnosed inflammatory breast cancer. Breast Cancer Research, 2015, 17, 2.	2.2	36
192	Use of Biomarkers to Guide Decisions on Systemic Therapy for Women With Metastatic Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline. Journal of Clinical Oncology, 2015, 33, 2695-2704.	0.8	279
193	IBC as a Rapidly Spreading Systemic Disease: Clinical and Targeted Approaches Using the Neoadjuvant Model. Journal of the National Cancer Institute Monographs, 2015, 2015, 56-59.	0.9	5
194	Molecular characterization and targeted therapeutic approaches in breast cancer. Breast Cancer Research, 2015, 17, 60.	2.2	132
195	Comprehensive genomic profiling of inflammatory breast cancer cases reveals a high frequency of clinically relevant genomic alterations. Breast Cancer Research and Treatment, 2015, 154, 155-162.	1.1	72
196	Prospective assessment of the prognostic value of circulating tumor cells and their clusters in patients with advanced-stage breast cancer. Breast Cancer Research and Treatment, 2015, 154, 563-571.	1.1	124
197	Inflammation Mediated Metastasis: Immune Induced Epithelial-To-Mesenchymal Transition in Inflammatory Breast Cancer Cells. PLoS ONE, 2015, 10, e0132710.	1.1	121
198	Circulating giant macrophages as a potential biomarker of solid tumors. Proceedings of the National Academy of Sciences of the United States of America, 2014, 111, 3514-3519.	3.3	229

#	ARTICLE	IF	CITATIONS
199	Biomarkers and Therapeutic Targets in Inflammatory Breast Cancer (IBC). <i>Current Breast Cancer Reports</i> , 2014, 6, 245-250.	0.5	2
200	Circulating tumor cells as early predictors of metastatic spread in breast cancer patients with limited metastatic dissemination. <i>Breast Cancer Research</i> , 2014, 16, 440.	2.2	94
201	Emergence of Constitutively Active Estrogen Receptor- β Mutations in Pretreated Advanced Estrogen Receptor-Positive Breast Cancer. <i>Clinical Cancer Research</i> , 2014, 20, 1757-1767.	3.2	529
202	CTC enumeration and characterization: moving toward personalized medicine. <i>Annals of Translational Medicine</i> , 2014, 2, 108.	0.7	83
203	Inflammatory breast cancer (IBC): clues for targeted therapies. <i>Breast Cancer Research and Treatment</i> , 2013, 140, 23-33.	1.1	71
204	Uncovering the Molecular Secrets of Inflammatory Breast Cancer Biology: An Integrated Analysis of Three Distinct Affymetrix Gene Expression Datasets. <i>Clinical Cancer Research</i> , 2013, 19, 4685-4696.	3.2	130
205	Genome Wide Proteomics of ERBB2 and EGFR and Other Oncogenic Pathways in Inflammatory Breast Cancer. <i>Journal of Proteome Research</i> , 2013, 12, 2805-2817.	1.8	38
206	Use of the FoundationOne next-generation sequencing (NGS) assay to detect actionable alterations leading to clinical benefit of targeted therapies for relapsed and refractory breast cancer.. <i>Journal of Clinical Oncology</i> , 2013, 31, 1009-1009.	0.8	8
207	Classifying circulating, mutation bearing tumor cells from breast cancer patients.. <i>Journal of Clinical Oncology</i> , 2013, 31, 580-580.	0.8	0
208	The class I HDAC inhibitor Romidepsin targets inflammatory breast cancer tumor emboli and synergizes with paclitaxel to inhibit metastasis. <i>Journal of Experimental Therapeutics and Oncology</i> , 2013, 10, 219-33.	0.5	31
209	Prognostic value of HER2-positive circulating tumor cells in patients with metastatic breast cancer. <i>International Journal of Clinical Oncology</i> , 2012, 17, 96-104.	1.0	80
210	Different gene expressions are associated with the different molecular subtypes of inflammatory breast cancer. <i>Breast Cancer Research and Treatment</i> , 2011, 125, 785-795.	1.1	68
211	Inflammatory Breast Cancer: The Disease, the Biology, the Treatment. <i>Ca-A Cancer Journal for Clinicians</i> , 2010, 60, 351-375.	157.7	298
212	Novel targeted therapies in inflammatory breast cancer. <i>Cancer</i> , 2010, 116, 2837-2839.	2.0	13
213	Phase II, Randomized Trial to Compare Anastrozole Combined with Gefitinib or Placebo in Postmenopausal Women with Hormone Receptor-Positive Metastatic Breast Cancer. <i>Clinical Cancer Research</i> , 2010, 16, 1904-1914.	3.2	154
214	Molecular mechanisms of metastasis in breast cancer—clinical applications. <i>Nature Reviews Clinical Oncology</i> , 2010, 7, 693-701.	12.5	208
215	The biological information obtainable from circulating tumor cells. <i>Breast</i> , 2009, 18, S38-S40.	0.9	30
216	Defining the Clinical Diagnosis of Inflammatory Breast Cancer. <i>Seminars in Oncology</i> , 2008, 35, 7-10.	0.8	56

#	ARTICLE	IF	CITATIONS
217	Inflammatory Breast Cancer: Defining a New Entity. <i>Seminars in Oncology</i> , 2008, 35, 6.	0.8	10
218	Detection of Circulating Tumor Cells in Peripheral Blood of Patients with Metastatic Breast Cancer: A Validation Study of the CellSearch System. <i>Clinical Cancer Research</i> , 2007, 13, 920-928.	3.2	1,204
219	Inflammatory breast cancer (IBC) and patterns of recurrence. <i>Cancer</i> , 2007, 110, 1436-1444.	2.0	194
220	Circulating tumor cells in metastatic breast cancer: biologic staging beyond tumor burden. <i>Clinical Breast Cancer</i> , 2007, 7, 471-9.	1.1	67
221	Circulating Tumor Cells versus Imagingâ€”Predicting Overall Survival in Metastatic Breast Cancer. <i>Clinical Cancer Research</i> , 2006, 12, 6403-6409.	3.2	728
222	Circulating Tumor Cells, Disease Progression, and Survival in Metastatic Breast Cancer. <i>Seminars in Oncology</i> , 2006, 33, 9-14.	0.8	163
223	Disease-free and overall survival after pathologic complete disease remission of cytologically proven inflammatory breast carcinoma axillary lymph node metastases after primary systemic chemotherapy. <i>Cancer</i> , 2006, 106, 1000-1006.	2.0	59
224	A nonreplicating adenoviral vector that contains the wild-typep53 transgene combined with chemotherapy for primary breast cancer. <i>Cancer</i> , 2006, 107, 935-944.	2.0	51
225	Circulating Tumor Cells at Each Follow-up Time Point during Therapy of Metastatic Breast Cancer Patients Predict Progression-Free and Overall Survival. <i>Clinical Cancer Research</i> , 2006, 12, 4218-4224.	3.2	937
226	Thyroid hormone and breast carcinoma. <i>Cancer</i> , 2005, 103, 1122-1128.	2.0	199
227	Invasive Lobular Carcinoma Classic Type: Response to Primary Chemotherapy and Survival Outcomes. <i>Journal of Clinical Oncology</i> , 2005, 23, 41-48.	0.8	352
228	Circulating Tumor Cells: A Novel Prognostic Factor for Newly Diagnosed Metastatic Breast Cancer. <i>Journal of Clinical Oncology</i> , 2005, 23, 1420-1430.	0.8	1,012
229	Circulating Tumor Cells, Disease Progression, and Survival in Metastatic Breast Cancer. <i>New England Journal of Medicine</i> , 2004, 351, 781-791.	13.9	4,124
230	Paclitaxel Improves the Prognosis in Estrogen Receptorâ€”Negative Inflammatory Breast Cancer: The M. D. Anderson Cancer Center Experience. <i>Clinical Breast Cancer</i> , 2004, 4, 415-419.	1.1	100
231	Update on the Management of Inflammatory Breast Cancer. <i>Oncologist</i> , 2003, 8, 141-148.	1.9	126
232	Angiogenesis modulation in cancer research: novel clinical approaches. <i>Nature Reviews Drug Discovery</i> , 2002, 1, 415-426.	21.5	158
233	Automated electrorotation to reveal dielectric variations related to HER-2/neu overexpression in MCF-7 sublines. <i>Clinical Cancer Research</i> , 2002, 8, 615-9.	3.2	49
234	Primary Inflammatory Carcinoma of the Breast. <i>American Journal of Roentgenology</i> , 2000, 174, 535-538.	1.0	53

#	ARTICLE	IF	CITATIONS
235	Phase I/II trial of high dose mitoxantrone in metastatic breast cancer: the M.D. Anderson Cancer Center experience. Breast Cancer Research and Treatment, 1999, 54, 225-233.	1.1	13